Does Calibrate Prescribe Wegovy® / Semaglutide?

What Calibrate Is and How Its Physician Network Works

Calibrate is a subscription-based metabolic health company that connects members with board-certified physicians through a telehealth model. Those physicians conduct a clinical evaluation and, where medically appropriate, write prescriptions for FDA-approved medications. Calibrate does not manufacture or dispense drugs itself. The prescribing decision rests entirely with the clinician assigned to each member's case.

The Role of the Calibrate Physician

A Calibrate-affiliated physician reviews your lab work, medical history, and metabolic risk factors before recommending any medication. This intake process mirrors the standard-of-care evaluation described in the 2023 American Association of Clinical Endocrinology (AACE) Obesity Algorithm, which calls for individualized pharmacotherapy selection based on comorbidities, contraindications, and patient preference. Garvey WT et al., Endocr Pract. 2023.

Physicians in the Calibrate network are not required to prescribe any single drug. They may choose from the full list of FDA-approved anti-obesity medications, including semaglutide 2.4 mg (Wegovy®), liraglutide 3 mg (Saxenda®), tirzepatide 2.5-15 mg (Zepbound®), naltrexone/bupropion (Contrave®), or phentermine/topiramate ER (Qsymia®), depending on what is clinically suitable.

How the Subscription Model Affects Prescribing

Calibrate's program fee covers coaching, curriculum access, and care coordination. It does not cover the cost of the medication itself, which is billed separately through your pharmacy and insurance. This structure means a physician may prescribe Wegovy® even if Calibrate's fee does not include it in a bundle. Members should confirm their insurance formulary before enrolling, since prior authorization for Wegovy® is required by most commercial payers.

Semaglutide: The Clinical Evidence Behind the Prescription

Semaglutide 2.4 mg (Wegovy®) received FDA approval for chronic weight management on June 4, 2021. The approval was based on the STEP clinical trial program, a series of four phase 3 randomized controlled trials enrolling adults with obesity or overweight plus at least one comorbidity. Understanding this evidence helps explain why a Calibrate physician may choose semaglutide over other agents.

STEP-1: The Landmark Efficacy Trial

In STEP-1 (N=1,961), adults without diabetes received once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. Participants in the semaglutide arm lost a mean of 14.9% of body weight versus 2.4% in the placebo arm (P<0.001). Wilding JPH et al., N Engl J Med. 2021;384(11):989-1002.

Roughly 69.1% of semaglutide participants lost at least 10% of body weight, compared with 12.0% of placebo participants. These numbers explain why GLP-1 receptor agonists now appear in the first-line pharmacotherapy recommendations of multiple major guidelines.

STEP-2: Efficacy in Type 2 Diabetes

STEP-2 (N=1,210) enrolled adults with type 2 diabetes and obesity. Semaglutide 2.4 mg produced a mean weight loss of 9.6% versus 3.4% with placebo at 68 weeks (P<0.001). Davies M et al., Lancet. 2021;397(10278):971-984. This result is clinically relevant for Calibrate members who have both obesity and type 2 diabetes, since the physician may weigh semaglutide's dual glycemic and weight benefit against other options.

Cardiovascular Outcomes: SELECT Trial Data

The SELECT trial (N=17,604) published in 2023 demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease but without diabetes (HR 0.80; 95% CI 0.72-0.90; P<0.001). Lincoff AM et al., N Engl J Med. 2023;389(24):2221-2232. This finding extended Wegovy®'s FDA-approved indications in March 2024 to include cardiovascular risk reduction.

Who Qualifies for a Wegovy® Prescription Through Calibrate

The FDA label for Wegovy® sets the minimum eligibility criteria. A prescribing physician, including one in Calibrate's network, must confirm that the member meets at least one of two thresholds before writing the prescription.

FDA Label Criteria

Per the FDA-approved prescribing information, Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with:

• An initial BMI of 30 kg/m² or greater, or
• An initial BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia.

FDA Wegovy® Prescribing Information.

Contraindications the Calibrate Physician Will Screen For

Wegovy® carries an FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The drug is also contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide. FDA Wegovy® Prescribing Information.

A Calibrate physician will also review pancreatitis history, gallbladder disease, heart rate, and psychiatric status before finalizing a prescription plan.

How Calibrate's Lifestyle Curriculum Interacts With Semaglutide

The clinical rationale for pairing GLP-1 pharmacotherapy with structured behavioral support is well-established. STEP-1 used a lifestyle intervention component alongside semaglutide in both arms. The drug arm still outperformed placebo by 12.5 percentage points, but the trial design reflects the guideline consensus that medication alone is not the standard of care for obesity management.

The Four Pillars Calibrate Uses

Calibrate organizes its non-pharmacological curriculum around four areas: food, sleep, exercise, and emotional health. Each module delivers behavioral strategies through video lessons and one-on-one coaching sessions with health coaches. The 2023 AACE Obesity Algorithm explicitly states that "comprehensive lifestyle intervention is the cornerstone of obesity treatment and should be incorporated into all treatment approaches," reinforcing the structural logic of Calibrate's design. Garvey WT et al., Endocr Pract. 2023.

What Happens When You Stop Semaglutide

STEP-4 (N=803) showed that participants who discontinued semaglutide after 20 weeks of treatment regained a mean of 6.9 percentage points of body weight over the following 48 weeks, compared with continued weight loss of 7.9 percentage points in those who remained on the drug. Rubino D et al., JAMA. 2021;325(14):1414-1425. This rebound effect is one reason Calibrate positions lifestyle change as a parallel track rather than an afterthought. Building durable behavioral habits may blunt weight regain if medication is later tapered or discontinued due to cost or tolerance.

Insurance, Cost, and Access Considerations for Calibrate Members

Wegovy® carries a list price of approximately $1,349 per month without insurance, making coverage the single largest access barrier for most patients. Calibrate has historically required members to carry commercial insurance and has designed its intake process around insurance verification as a first step.

Prior Authorization Requirements

Most commercial insurance plans require prior authorization for Wegovy®. Criteria typically include documented BMI thresholds, evidence of prior weight-loss attempts, and absence of listed contraindications. Medicare Part D currently does not cover weight-loss medications under existing statutory exclusions, though the Treat and Reduce Obesity Act has been reintroduced in Congress multiple times. Medicaid coverage varies by state. FDA Wegovy® Prescribing Information.

The Novo Nordisk Savings Card

Novo Nordisk offers a savings program for commercially insured patients that may reduce out-of-pocket costs to as low as $25 per month for eligible individuals. Patients without insurance coverage do not qualify for this program. Calibrate's care team may assist with prior authorization paperwork, but approval is ultimately decided by the insurer.

Compounded Semaglutide: What Calibrate Does Not Do

During the FDA-declared shortage period for semaglutide (which officially ended for Wegovy® 2.4 mg in May 2023), some telehealth platforms prescribed compounded semaglutide from 503A or 503B pharmacies. The FDA has stated that compounded semaglutide products are not FDA-approved and do not have the same safety and efficacy guarantees as Wegovy® or Ozempic®. FDA Statement on Compounded Semaglutide, 2024. Calibrate's physician-led model and insurance-first structure generally routes members toward branded, FDA-approved products rather than compounded alternatives.

Alternatives Calibrate Physicians May Prescribe Instead of Wegovy®

When Wegovy® is unavailable, unaffordable, or clinically contraindicated, a Calibrate physician may consider one of several alternatives. The table below outlines the options most likely to appear in a Calibrate clinical encounter.

| Medication | Mechanism | Mean Weight Loss (RCT) | FDA Approval | |---|---|---|---| | Wegovy® (semaglutide 2.4 mg) | GLP-1 agonist | 14.9% at 68 wk (STEP-1) | 2021 | | Zepbound® (tirzepatide 15 mg) | GIP/GLP-1 dual agonist | 20.9% at 72 wk (SURMOUNT-1) | 2023 | | Saxenda® (liraglutide 3 mg) | GLP-1 agonist | 8.0% at 56 wk (SCALE Obesity) | 2014 | | Qsymia® (phentermine/topiramate ER) | Sympathomimetic/carbonic anhydrase inhibitor | 10.9% at 56 wk (EQUIP) | 2012 | | Contrave® (naltrexone/bupropion) | Opioid antagonist/dopamine reuptake inhibitor | 5.0% at 56 wk (COR-I) | 2014 |

Tirzepatide as a Wegovy® Alternative

Tirzepatide (Zepbound®) has emerged as a close comparator to semaglutide in weight management. SURMOUNT-1 (N=2,539) reported a mean weight loss of 20.9% at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo (P<0.001). Jastreboff AM et al., N Engl J Med. 2022;387(3):205-216. A Calibrate physician may consider tirzepatide for members who have not responded adequately to semaglutide or whose insurance formulary favors Zepbound® over Wegovy®.

Liraglutide for Members Who Cannot Tolerate Weekly Injections

Liraglutide 3 mg (Saxenda®) is administered daily rather than weekly and may be preferred for members who find weekly depot injections difficult to manage. SCALE Obesity and Prediabetes (N=3,731) showed a mean weight loss of 8.0% versus 2.6% with placebo at 56 weeks. Pi-Sunyer X et al., N Engl J Med. 2015;373(1):11-22. Liraglutide's shorter half-life allows faster dose adjustment if side effects emerge.

Common Side Effects of Semaglutide That Calibrate Members Should Know

Gastrointestinal adverse effects are the most frequently reported side effects with semaglutide 2.4 mg. In STEP-1, nausea occurred in 44% of semaglutide participants versus 16% of placebo participants. Vomiting occurred in 24% versus 6%, and diarrhea in 30% versus 16%. Wilding JPH et al., N Engl J Med. 2021;384(11):989-1002.

Managing GI Side Effects

The 4-week dose escalation schedule built into the Wegovy® prescribing information reduces, but does not eliminate, GI burden. Starting at 0.25 mg weekly and escalating every 4 weeks to the 2.4 mg maintenance dose over approximately 16 to 20 weeks gives the gut time to adapt. Calibrate coaches may provide dietary guidance during the escalation phase, such as smaller meal portions, lower-fat food choices, and avoiding lying down after eating.

Rare but Serious Risks

Acute pancreatitis has been reported in patients taking GLP-1 receptor agonists, though a causal relationship has not been established in large trials. Gallbladder disease, including cholelithiasis and cholecystitis, occurred more frequently with semaglutide than placebo in STEP-1 (2.6% vs. 1.2%). Wilding JPH et al., N Engl J Med. 2021;384(11):989-1002. Calibrate physicians are expected to counsel members on these risks during the prescribing consultation.

What the HealthRX Medical Team Recommends Before Joining Calibrate for Semaglutide

Before enrolling in any telehealth program specifically to access semaglutide, a few preparatory steps can significantly increase the likelihood that the clinical visit results in a prescription and that insurance covers it.

Step 1: Verify Your Insurance Formulary

Call the member services number on your insurance card and ask specifically whether Wegovy® (NDC 00169-4960-12 for the 2.4 mg pen) appears on your formulary, what tier it is on, and what prior authorization criteria apply. This call takes roughly 15 minutes and prevents the most common enrollment disappointment.

Step 2: Gather Supporting Documentation

Collect any records of prior weight-loss attempts, body weight history, and diagnoses of comorbidities such as hypertension, prediabetes, or sleep apnea. Prior authorization reviewers often require evidence of 6 or more months of structured lifestyle intervention before approving GLP-1 medications.

Step 3: Confirm Your BMI Eligibility

Wegovy® is FDA-indicated for BMI 30 or above, or BMI 27 or above with a qualifying comorbidity. Calculate your BMI at NIH BMI Calculator before the intake visit so you arrive with accurate numbers.

Step 4: Ask the Calibrate Physician Directly

During your consultation, ask specifically whether Wegovy® or an alternative semaglutide product is the planned prescription and what the process is if your insurance denies the prior authorization. A clear answer to that question before you pay any program fees prevents surprises later.